Timing of SGLT2i initiation after acute myocardial infarction

[1]  H. Sourij,et al.  Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial , 2023, Cardiovascular Diabetology.

[2]  H. Sourij,et al.  Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial , 2023, Cardiovascular Diabetology.

[3]  R. Bellomo,et al.  Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study , 2023, Critical Care.

[4]  Keming Huang,et al.  Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms , 2023, Cardiovascular Diabetology.

[5]  G. Paolisso,et al.  SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis , 2023, Cardiovascular Diabetology.

[6]  G. Paolisso,et al.  SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes , 2023, BMC Medicine.

[7]  R. Marfella,et al.  Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry , 2022, Pharmacological research.

[8]  R. Holman,et al.  Empagliflozin in acute myocardial infarction: the EMMY trial , 2022, European heart journal.

[9]  Deepak L. Bhatt,et al.  Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence , 2022, Diabetes, obesity & metabolism.

[10]  Deepak L. Bhatt,et al.  Empagliflozin in Patients Post Myocardial Infarction Rationale and Design of the EMPACT-MI Trial. , 2022, American heart journal.

[11]  P. Ponikowski,et al.  The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial , 2022, Nature Medicine.

[12]  Que Zhu,et al.  The benefits of sacubitril–valsartan in patients with acute myocardial infarction: a systematic review and meta‐analysis , 2021, ESC heart failure.

[13]  15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2021. , 2021, Diabetes care.

[14]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[15]  G. Hindricks,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[16]  M. Panteghini,et al.  Inside ST-elevation myocardial infarction by monitoring concentrations of cardiovascular risk biomarkers in blood. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[17]  S. Normand,et al.  Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. , 2009, JAMA.

[18]  C. Hamm,et al.  Release pattern of N–terminal pro B–type natriuretic peptide (NT–proBNP) in acute coronary syndromes , 2006, Clinical Research in Cardiology.

[19]  K. Mahaffey,et al.  ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation , 2012 .

[20]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..